sulfinpyrazone Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory analgesics, phenylbutazone derivatives 2528 57-96-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • sulfinpyrazone
  • diphenylpyrazone
  • sulfinpyrazon
  • sulfoxyphenylpyrazolidine
  • sulphinpyrazone
  • sulfoxyphenylpyrazolidin
A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
  • Molecular weight: 404.48
  • Formula: C23H20N2O3S
  • CLOGP: 1.66
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 0
  • TPSA: 57.69
  • ALOGS: -3.10
  • ROTB: 6

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.30 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.03 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 39 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 28.25 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.12 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.34 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.02 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 6.20 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 13, 1959 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
ATC M04AB02 MUSCULO-SKELETAL SYSTEM
ANTIGOUT PREPARATIONS
ANTIGOUT PREPARATIONS
Preparations increasing uric acid excretion
MeSH PA D018501 Antirheumatic Agents
MeSH PA D006074 Gout Suppressants
MeSH PA D014528 Uricosuric Agents
CHEBI has role CHEBI:35841 uricosuric agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hyperuricemia indication 35885006 DOID:1920
Chronic gouty arthritis indication 68451005
Renal colic contraindication 7093002
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Dehydration contraindication 34095006
Gastrointestinal ulcer contraindication 40845000
Kidney disease contraindication 90708001 DOID:557
Urolithiasis contraindication 95566004
Chronic peptic ulcer contraindication 128287004
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Acute peptic ulcer contraindication 196682000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.92 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Solute carrier family 22 member 12 Transporter INHIBITOR IC50 4 CHEMBL CHEMBL
fMet-Leu-Phe receptor GPCR Ki 4.70 WOMBAT-PK
Multidrug resistance-associated protein 1 Transporter WOMBAT-PK

External reference:

IDSource
4018786 VUID
N0000147089 NUI
D00449 KEGG_DRUG
4018786 VANDF
C0038742 UMLSCUI
CHEBI:9342 CHEBI
CHEMBL832 ChEMBL_ID
D013442 MESH_DESCRIPTOR_UI
5342 PUBCHEM_CID
777 INN_ID
DB01138 DRUGBANK_ID
V6OFU47K3W UNII
10205 RXNORM
2070 MMSL
5530 MMSL
d00380 MMSL
002322 NDDF
19261005 SNOMEDCT_US
387108008 SNOMEDCT_US

Pharmaceutical products:

None